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Abstract 
 
The gene for insulin-like growth factor two, IGF2 is maternally imprinted. 
Fifteen heterozygous samples were analyzed for the IGF2 imprinting status and 
promoter usage. IGF2 LOI was detected in four non-tumorous tissues and in six 
laryngeal squamous cell carcinoma (LSCC) tumors. There was no clear pattern of 
specific promoter activity in LSCC tumors and the adjacent normal tissues. P1 
promoter usage was active in eight LSCCs, among them four with LOI. As it was 
activated in four tumors with maintenance of imprinting (MOI) and four non-tumors, 
we concluded that P1 promoter is not exclusively connected with IGF2 LOI in LSCC. 
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1. Introduction 
 
Genomic imprinting is a parental origin-specific chromosomal modification 
which causes differential expression of maternal and paternal alleles. IGF2 is a 
mitogenic peptide which exerts its bioactivity through binding to the type I IGF 
receptor. The gene encoding IGF2 (IGF2) is maternally imprinted with only paternal 
allele being transcribed. It is overexpressed in a wide variety of neoplasms and it is 
thought to serve as autocrine tumor enhancer [1]. Using SAGE technology, Zhang et 
al. showed that IGF2 transcripts were 73 times more abundant in colorectal cancer 
tissue than in non-tumorous tissue [2].  
The IGF2 spans 30 kb of chromosomal DNA and is located on chromosome 
11 (11p15.5). It consists of nine exons and only exons 7, 8 and the 5' part of exon 9-
encode the IGF2 prepro-protein. Exons 1, 4, 5 and 6 are preceded by separate 
promoters (P1-P4) that give rise to a family of IGF2 mRNA species of different 
length. The activity of these promoters is regulated in a tissue- and developmental-
specific manner. In prenatal and early postnatal liver and chondrocytes, IGF2 
transcripts from the P1 promoter are always derived from both parental alleles, 
whereas transcripts from the P2-P4 promoters are always active from one parental 
allele [3, 4]. In adult liver, P1 promoter activity is increased. It is equally active on 
both alleles and encompasses the entire IGF2 transcriptional unit (including P2-P4 
promoter sequences) [4]. Loss of IGF2 imprinting (IGF2 LOI) could then result from 
promoter switching if transcription from the imprinted promoters P2-P4 declines and 
transcription from the non-imprinted promoter P1 increases.  
It is not clear whether the usage of the IGF2 promoters changes with the 
progression of some malignant tumors. To date, it has not been clarified whether 
promoter usage is altered in laryngeal squamous cell carcinoma (LSCC) as compared 
with normal laryngeal tissue.   
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2. Materials and methods 
 
2.1. Tissue samples 
 
Tissue samples were obtained from the University Hospital “Sestre 
milosrdnice”, Zagreb, Croatia, during surgical procedures. All patients were male, 
ages 46-83, with diagnosed laryngeal squamous cell carcinoma. TNM staging was 
performed at the Department of Pathology “Ljudevit Jurak”. Informed consent was 
signed by all patients. The tissues were quickly frozen in liquid nitrogen and stored at 
-80ºC until analysis.  
 
2.2. Genomic DNA and total RNA extraction 
 
Approximately 1 cm3 of frozen tissue was used for the extraction of genomic 
DNA by the phenol-chloroform method [5]. For total RNA extraction, tissue was 
homogenized in RNA-Bee reagent (Biogenesis Ltd. Poole, England) and total RNA 
was extracted according to the manufacturer’s instructions. It was further purified by 
using a RNeasy® Mini kit (Qiagen, USA). RNA was treated on column with DNase 
(Qiagen, RNase-free DNase set) in order to remove traces of contaminating DNA. 
RNA integrity was determined by electrophoresis on a 1% agarose gel. 
 
2.3. Identification of genomic IGF2 ApaI polymorphism 
 
Genomic DNA was isolated from non-tumorous tissues and analyzed for 
heterozygosity for the ApaI restriction site in the IGF2. For this purpose, primers 
ApaIF: 5`CTTGGACTTTGAAGTCAAATTGG 3` and ApaIR: 5`ATCGTTGTTG 
GGTCTGACCGAGGAG 3’ were used for the amplification of 173 bp long segment 
of exon 9. The 25 µl reaction mixture contained: dNTPs (50 µM each), 1.5 mM 
MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 8 pmol of each primer and 0.25 U of 
rTaq polymerase (TaKaRa). A total of 38 cycles was performed. One cycle consisted 
of denaturation at 95ºC for 30s, annealing at 57ºC for 30s and primer extension at 
72ºC for 30s (+ 1s in every subsequent cycle). The PCR product was digested 
overnight with 10 U of ApaI (Roche), yielding 173 bp fragment (homozygote - uncut), 
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108 and 65 bp fragments (homozygote - cut) or 173, 108 and 65 bp (heterozygote - 
one allele cut, another uncut). Digested PCR products were electrophoresed through 
10% polyacrilamide gel and visualized by silver staining [6]. 
 
2.4. Analysis of IGF2 expression and imprinting status 
 
One microgram of total RNA was reversely transcribed using 0.5 µg/µl 
oligo(dT)18 (New England BioLabs), 0.5 mM dNTPs, 20 U of RNase inhibitor 
(Roche), 1x incubation buffer (supplied with M-MuLV enzyme: 75 mM KCl, 50 mM 
Tris-HCl, 3 mM MgCl2, 10 mM dithiotreitol; pH 8.3) and 40 U of M-MuLV reverse 
transcriptase (New England Biolabs) in total volume of 20 µl. RT PCR cycle 
consisted of pre-incubation of RNA with oligo(dT)18 at 70ºC for 10 minutes and 
incubation at 37ºC for one hour. 
The quality of cDNA was checked by amplifying part of the housekeeping 
gene, GAPDH, with primers GAPDH1: 5' AACGGATTTGGTCGTATTGGGC 3’ 
which is located on border between the first and the second exon and GAPDH2: 5' 
AGGGATGATGTTCTGGAGAGCC 3’ which is located in exon seven. An 
additional check, this time for DNA contamination, was made with primers GAPDH2 
and GAPDH3: 5'AAGCTGACTCAGCCCGCAAAGG3' which is complementary to 
DNA sequence in intron five. The 25 µl reaction mixture contained dNTPs (50 µM 
each), 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 6 pmol of each primer 
and 0.25 U of rTaq polymerase (TaKaRa). Forty-two cycles were performed with the 
annealing temperature of 56ºC. The PCR products (sizes 605 and 642 bp, 
respectively) were electrophoresed through 1% agarose gel and stained by ethidium 
bromide (0.5 µg/ml). 
Successfully transcribed cDNA, free of contaminating genomic DNA, was 
then amplified with primers ApaIF and ApaIR. The PCR product was 173 bp long. 
Amplicons were digested with ApaI, as already described, and run through 10% 
polyacrilamide gel. Bands were visualized by silver staining.    
 
2.5. Promoter specific expression of IGF2 
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Promoter specific expression was analyzed only on samples showing IGF2 
expression (mono- or biallelic). Promoter-specific sense primers were used to evaluate 
transcription of IGF2 from four promoters:  
P1S:5' CGAATTCTGGGCACCAGTGACTCCCCG 3' located in exon two (GenBank 
accession number X03423); P2S: 5'ACCGGGCATTGCCCCCAGTCTCC3’ located 
in exon four (GenBank accession number X03562), P3S: 5' 
CGTCGCACATTCGGCCCCCGCGACT 3’ located in exon five (GenBank 
accession number X03562) and P4: 5' TCCTCCTCCTCCTGCCCCAGCG 3’ located 
in exon six (GenBank accession number X03562). The common antisense primer was 
PR: 5’ CAAGAAGGTG AGAAGCACCAGCAT 3’ [7] located in exon seven 
(GenBank accession number: X03562). The sizes of PCR products were 376 bp, 254 
bp, 186 bp and 134 bp respectively. Touchdown PCR was performed as follows: in 
the first 13 cycles annealing temperature was getting lower for 1ºC starting from 
68ºC, followed by 25 cycles with the annealing temperature at 55ºC. PCR products 
were loaded on 2% agarose gel and stained with ethidium bromide. 
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3. Results 
 
We have analyzed 15 LSCC tumors and comparable normal tissues to 
determine IGF2 imprinting status and promoter usage. In most specimens (7 out of 
12), the tumorous and non-tumorous tissues did not have the same pattern of promoter 
usage (Table 1). The most frequently active promoter in non-tumorous tissues 
(denominated NT) was P3 (10 out of 12 samples), followed by P4 promoter (9 out of 
12 samples). Therefore, we concluded that, in the majority of normal laryngeal 
tissues, P3 and P4 promoters directed transcription of IGF2. Unexpectedly, P1 
promoter was active in four non-tumorous samples: two with retained IGF2 
imprinting (NT3 and NT8) (Fig.1) but also in two specimens showing biallelic 
expression of IGF2 (NT11 and NT14). In sample NT8, it was the only active 
promoter. However, in sample NT11, P3 promoter was also activated and, in samples 
NT3 and NT14, transcription was directed from all three of them. P3 promoter was 
active alone in sample NT2. P4 promoter was active alone in sample NT5. A 
combination of P3 and P4 promoters occurred in 50% of the samples (NT1, NT4, 
NT6, NT7, NT13 and NT15).  
In tumor specimens, the most frequently used promoter was P4 (11/15), 
followed by P3 (10/15) and P1 promoters (8/15). P1 promoter was used in four out of 
six tumors that expressed IGF2 biallelically (T9, T11, T12 and T14). It was also 
active in other four tumors (T1, T2, T6 and T10) which maintained IGF2 imprinting. 
In three samples, P1 promoter was active alone and others were shut down (T1, T2 
and T6). In more than a half of the samples, P1 promoter was used in combination 
with P3 (T11), P4 (T10) or both of them (T9, T12 and T14). P3 promoter was not 
active alone in either tumor specimen. P4 promoter was active alone in one sample 
(T7) while a combination of both promoters occurred in six tumors (T3, T4, T5, T8, 
T13 and T15).  
We did not detect expression from P2 promoter at all. 
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4. Discussion 
 
We noticed biallelic expression of IGF2 in four non-tumorous tissues. Our 
results are consistent with results from Cui et al., who found IGF2 LOI in both the 
normal tissue and tumor of patients with colorectal cancer (CRC) [8]. Also, the odds 
of LOI in normal tissue of individuals with a family history of CRC, were 5.15 times 
that of individuals without it. The odds of LOI in participants with a personal history 
of CRC were 4.72 times that of participants without it [9]. These data suggest that loss 
of IGF2 imprinting leads to an oncogenic diathesis that enhances the risk of 
neoplastic transformation [10]. Hence, we consider non-tumorous tissues with 
biallelic IGF2 expression (although morphologically unchanged) epigenetically 
changed. This phenomenon might be the first step in the neoplastic transformation on 
this model as proposed for the CRC [9]. 
P1 promoter was active in non-tumorous tissue in specimens with monoallelic 
(NT3 and NT8) and biallelic IGF2 expression (NT11 and NT14). Activity and 
imprinting of the IGF2 P1 promoter apparently occurs in a tissue-specific manner 
since it is not active in cervical tissue [11], benign bladder, breast and prostate tissue 
[12]. Its activity was shown in pons [13] and in adult skeletal muscle tissue [14] 
where IGF2 is expressed monoallelically. In addition, in adult human liver and 
chondrocytes [3, 4], P1 governs biallelic transcription.  
We detected the activity of P1 promoter in eight laryngeal tumor samples. 
Among them were four with LOI (T9, T11, T12 and T14). We concluded that the 
activity of P1 promoter is upregulated in LSCC tumors but apparently is not causing 
LOI because only half of LOI tumors expressed IGF2 from P1. Relationship between 
P1 promoter usage and IGF2 LOI apparently differs between types of tumors. For 
example, in Wilms’ tumors P1 transcripts were present in all LOI tumors but also in 
some MOI tumors [15]. In cervical carcinoma tissues P1 promoter (sometime in 
combination with P3) was used only in carcinoma tissues in which IGF2 LOI 
occurred [11]. In rhabdomyosarcoma tumors expression from P1 promoter was 
detected in 20% of IGF2 LOI tumors and in 30% of MOI tumors [16]. Unexpectedly, 
in three LSCC tumors (T1, T2 and T6) the IGF2 was imprinted (only allele “a” was 
transcribed) from the P1 promoter. Although this result does not correlate with the 
well known hypothesis: “P1 active – biallelic expression present”, there are results in 
the literature that are similar to ours [15, 16]. One possible explanation is that there 
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are tissues and developmental specific factors which can modulate the imprinting 
signal responsible for the differential IGF2 allelic expression [15], even more because 
we have shown this phenomenon in one non-tumorous tissue (NT8). It would be of 
great interest to study the methylation pattern in these samples by the bisulfite 
sequencing method. 
Our results are also contrary to the finding of Issa et al. who demonstrated a 
switch, caused by the spreading of methylation from maternal to paternal IGF2 P2-P4 
promoters associated CpG island, from P2-P4 promoters to P1 promoter during 
carcinogenesis [17].  
In non-tumorous laryngeal samples, we detected the activity of different 
promoters at the same time. We do not know which promoter governed biallelic 
expression in samples with IGF2 LOI because previous observations demonstrated 
that P3 promoter could also direct biallelic expression [12, 15, 18, 19].  
Expression from P2 promoter was not found at all. P2 promoter is active 
during fetal life [20] and the level of mRNA directed from P2 is quite low in all 
tissues and cell lines. One might ask what its physiological role in adult tissues is 
[21]. The mechanism of regulation of P2 promoter activity is still unclear [20]. Von 
Horn et al. showed that acute growth hormone (GH) treatment doubles transcription 
from P2 promoter in adult human liver [21]. Most of our patients were older than 60 
years, so an explanation for no detection of P2 mRNA could be the silencing of P2 
promoter during aging.  
Finding that in normal laryngeal tissues P3 and P4 were the most active 
promoters is in line with the results of Mineo et al. who demonstrated that, by using 
semi-quantitative RT-PCR, expression from P3 and P4 promoters predominates in 
human benign bladder, prostate and breast tissue [12]. 
Transcription from P3 promoter is also upregulated in such human tumors as: 
hepatoblastoma [22], Wilms’ tumor [23], breast, prostate and bladder cancers [12]. 
The proximal region of P3 promoter contains several methylation-regulated 
transcription factor binding sites, important for the regulation of its activity [24]. In 
LSCC samples, P3 activity, when present (in 10 out of 15 samples), was always 
joined with the activity of P4 (T3, T4, T5, T8, T13 and T15), P1 (T11) or P1 and P4 
promoters (T9, T12 and T14). When comparing three tumorous and non-tumorous 
tissues retaining imprinting (samples 1, 2 and 6), transcription from P3 promoter, 
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present in non-tumorous tissue, was replaced with P1 promoter activation in tumorous 
tissues. The reason for this switch in laryngeal tumors could be hypermethylation.  
In conclusion, the usage of promoters differs in laryngeal squamous cell 
carcinomas when compared with non-tumorous tissues. There is no clear pattern of 
IGF2 promoter usage either in laryngeal tumors or in adjacent normal tissues, 
although P1 was more frequently active in tumors than in normal tissue. Our study 
also demonstrates that IGF2 promoter usage is highly variable in malignant and 
adjacent normal laryngeal tissue and that P1 promoter usage is not responsible for 
IGF2 LOI in LSCC. 
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Tables 
 
 
Table 1: Results of promoter usage in tumor and matched non-tumorous tissue 
sample IGF2 expression P1 P3 P4 
NT1 allele a  active active 
T1 allele a active   
NT2 allele a  active  
T2 allele a active   
NT3 allele b active active active 
T3 allele b  active active 
NT4 allele a  active active 
T4 allele a  active active 
NT5 allele a   active 
T5 allele a  active active 
NT6 allele a  active active 
T6 allele a active   
NT7 allele a  active active 
T7 allele a   active 
NT8 allele a active   
T8 allele a  active active 
NT9 no expression    
T9 alleles a and b active active active 
NT10 no expression    
T10 allele a active  active 
NT11 alleles a and b active active  
T11 alleles a and b active active  
NT12 no expression    
T12 alleles a and b active active active 
NT13 alleles a and b  active active 
T13 alleles a and b  active active 
NT14 alleles a and b active active active 
T14 alleles a and b active active active 
NT15 alleles a and b  active active 
T15 alleles a and b  active active 
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Figure legend 
 
Fig. 1. Lanes 1- 4: Promoter usage in non-tumorous tissue NT3 where promoters P1 
(376 bp, lane 1), P3 (186 bp, lane 3) and P4 (134 bp, lane 4) direct monoallelic 
transcription of IGF2. Lanes 6 - 9: Promoter usage in tumor T3 (monoallelic 
expression), promoter P1 is silenced (lane 6) and promoters P3 (186 bp, lane 8) and 
P4 (134 bp, lane 9) are active. The expression from promoter P2 (lanes 2 and 7) was 
not detected. Lane 10: HaeIII digest of ΦX174 DNA (New England BioLabs); lane 5: 
marker V (Roche). 
 
 
 
